1Dellinger RP, Levy MM, Cadet JM, et al. Surviving sepsis campaign : International guidelines for management of severe sepsis and septic shock : 2008 [ J ]. Crit Care Med,2008,36 ( 1 ) :296 - 327.
2Kumar A. Optimizing antimicrobial therapy in sepsis and septic shock [J]. Crit Care Clin, 2009,25 (4) :733 - 751.
3Kung HC, Hoyert DL, Xu J, et al. Deaths: Final data for 2005 [ J]. Natl Vital Stat Rep, 200g ,56(10) :1 - 120.
5Macarthur RD, Miller M, Albertson T, et aL Adequacy of early empiric antibiotic treatment and survival in severe sepsis: Experience from the MONARCS trial[ J]. Clin lnfect Dis,2004,38 (2) :284 -288.
6Deresinski S. Principles of antibiotic therapy in severe infections: Opti- mizing the therapeutic approach by use of laboratory and clinical data [ J ]. Clin Infect Dis,2007,45 (suppl 3 ) :177 - 183.
7Rojas MX, Granados C. Oral antibiotics versus parenteral antibiotics for severe pneumonia in children [ J ]. Cochrane Database Syst Rev, 2006 ( 2 ) : CD004979.
8Mccracken GH Jr. New era for orally administered antibiotics : Use of se- quential parenteral - oral antibiotic therapy for serious infectious disea- ses of infants and children[ J]. Pediatr Infect Dis J, 1987,6(10) :951 - 953.
10American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital - acquired, ventilator - associated, and healthcare - associated pneumonia [ J ]. Ant J Respir Crit Care Meal,2005,171 (4) :388 -416.
2Jacobs MR. How we predict bacterial eradication? [J]. Int J Infect Dis, 2003, S1:13-20.
3Brook I. Use of oral cephalosporins in the treatment of acute otitis media in chihtren [J]. Int J Anlimicorb Agents, 2004 , 24 ( 1 ): 18-23.
4Munekhof WJ, Carney J, Neilsnn G, el al. Continuous infusion of ticareillin-elavulanate for home treatment of serious infections: clinical efficacy, safety, pharmacokinetics and pharmacndynamics[J], Int J Antimicrub Agents,2005 ,25(6):514-522.
5Moulon JW, Vinks AA. Conlinuous infusion of beta-lactams [J]. Curr Opin Crit Care, 2007, 13(5):598-606.
6Jafuratanasirikul S, Sriwiriyajan S, Punyn J. Comparison of the pharmacodynanfics of meropenem in patients wilh ventilator-associaled pneumonia following adminstfation by 3-hour infusion or bolus injection [J]. Antimicrob Agents Chemother, 2005,49 (4):1337-1339.
7Kuti JL, Maglio D, Nightingale CH, el al. Economic benefit of a meropenem dosage slralegy hased on pharmaeodynamie concept[J]. Am J Health Syst Pharm, 2003.60(6) :565-568.
8Lorente L, Lorenzo L, Martin MM, et al. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli [J]. Ann Pharmacother, 2006, 40(2):219-223.
9Hnat M, Bawdon RE. Transfer of meropenem in the ex vivo human placenla perfusion model [J]. Infect Dis Obstet Gynecol, 2005,13 (4) :223-227.
10Smilh DL, Bauer SM, Nicolau DP. Stability of meropenem in polyviny chloride bags and an elaslomeric infusion device [J]. Am J Health Syst Pharm,2004,61 ( 16):1682-1685.
7IGUCHI A, NAGAYA Y, PRADEL E, et al. Genome evolu- tion and plasticity of serratia marcescens, an important multidrug-resistant nosocomial pathogen [ J ]. Genome Biol Evo1,2014,6 (8) :2096-2110.
8Britt N S, Steed M E, Potter E M, et al. Tigecycline for the treatment of severe and severe complicated clostridium difficile infection [J]. Infectious Diseases & Therapy, 2014, 3(2): 321-331.
9Kopterides P, Papageorgiou C, Antoniadou A, et al. Failure of tigecycline to treat severe Clostridium difficile infection [J]. Anaesth Intensive Care, 2010, 38(4): 755-758.
10Kuitert P C, Abbink F C, Broers C J, et al. Epstein-Barr virus infection with severe consequences. EBV, hae mophagocytic lymphohistiocytosis and Hodgkin lympho- ma with down syndrome[J]. Ned Tijdschr Geneeskd, 2014,158=A7608.
